

f2

(12) **UK Patent Application** (19) **GB** (11) **2 299 025** (13) **A**

(43) Date of A Publication **25.09.1996**

(21) Application No **9607420.8**

(22) Date of Filing **16.03.1993**

Date Lodged **10.04.1996**

(30) Priority Data

(31) **9205800** (32) **17.03.1992** (33) **GB**

(62) Derived from Application No. **9305344.5** under Section 15(4) of the Patents Act 1977

(71) Applicant(s)

British Technology Group Limited

(Incorporated in the United Kingdom)

**101 Newington Causeway, LONDON, SE1 6BU,
United Kingdom**

(72) Inventor(s)

Mark William James Ferguson

(51) INT CL⁶

A61K 9/06 9/08 9/10

(52) UK CL (Edition O)

A5B BLB BLD B28Y B281 B823

U1S S2416

(56) Documents Cited

GB 1311956 A WO 91/09604 A1 WO 90/01938 A1

Chemical Abstracts 119:15132 & JP 050058868 A2

(58) Field of Search

UK CL (Edition O) A5B BFE BHA BKE BLB BLD BLF

INT CL⁶ A61K 9/06 9/08

ONLINE: WPI, DIALINDEX(MEDICINE), CAS-ONLINE

(74) Agent and/or Address for Service


R K Percy

**British Technology Group Limited, Patent Services,
101 Newington Causeway, LONDON, SE1 6BU,
United Kingdom**

(54) **Formulations of mannose phosphates useful in the treatment of fibrotic disorders**

(57) Mannose-6- and 1-phosphates and their pharmaceutically acceptable salts and bioprecursors thereof are useful in the treatment of fibrotic disorders. They accelerate wound healing and the 6-phosphate prevents or mitigates scar formation. The invention includes particular, appropriate formulations of the mannose phosphate, viz. creams, ointments, gels, sterile injectable or syringeable solutions and eyedrops.

GB 2 299 025 A



FORMULATIONS OF MANNOSE PHOSPHATES USEFUL IN
THE TREATMENT OF FIBROTIC DISORDERS

Background of the invention

5 **1. Field of the invention**

This invention relates to formulations of certain known compounds useful for healing wounds and treating certain other conditions associated with the accumulation of extracellular matrix in tissue.

2. Description of the related art

10 It is a problem that although wounds in humans and other mammals usually heal reasonably quickly, unsightly scar tissue is often formed. It is known that growth factors are implicated in fibrotic disorders. Various proposals have been made to ameliorate the effects of fibrotic disorders by administering either the growth factor or antibodies thereto. See, for example W.A. Border *et al.*, Nature 346 371-374 (1990), who showed that
15 extracellular matrix production in acute mesangial proliferative glomerulonephritis (inflammation of the kidney believed caused by immunological injury to cells) is associated with increased production of transforming growth factor (TGF)- β 1 and suppressed by administering anti-TGF- β 1. E. Kovacs, Immunology Today 12 (1) 17-23 (1991) concludes that blocking the effects of certain cytokines (such as TNF- α) with antibodies has
20 diminished fibrosis in animal models of tissue injury. PCT Application Publication No. WO 91/04748 (La Jolla Cancer Research Foundation) proposes to treat pathologies associated with accumulation of extracellular matrix in tissue with platelet derived growth factor (PGDF) or with antibodies to TGF- β 1. The diseases treated are in general fibrotic diseases and include glomerulonephritis, adult respiratory distress syndrome, cirrhosis of
25 the liver, fibrocytic disease, fibrosis, fibrotic cancers, fibroids, fibroadenomas and fibrosarcomas. Other fibrotic conditions are mentioned. Also, the method can be used to treat or prevent excessive scarring such as keloid scars (hard, irregular scar tissue in the skin which forms when a wound is under tension) and/or is produced in genetically pre-disposed people. M. Shah, D.M. Foreman and M.W.J. Ferguson,
30 The Lancet 339, 213-214 (Jan 25, 1992), describe the control of scarring in wounds by administering antibody which neutralises TGF- β 1 and - β 2.

The biological mechanisms by which the growth factors operate is not well understood, see C.C. Bascom *et al.*, Molecular and Cellular Biology 9, 5508-5515 (1989).

It is known that TGF- β 1 is synthesised as a pre-pro-protein of 390 amino acids which is converted to mature protein by cleavage between aa residues 278 and 279.

- 5 However, TGF- β 1 isolated *in vivo* is found predominantly as a high molecular weight latent complex (LTGF- β 1) in which the pro-region is still associated with the mature molecule, despite the cleavage of the peptide bond. TGF- β 2 and β -3 also have latent forms. All have been shown to bind to a plasma membrane receptor called the cation-independent mannose-6-phosphate/insulin-like growth factor II receptor. Binding occurs through
- 10 mannose-6-phosphate residues attached at glycosylation sites within the pro-region and, in the case of TGF- β 1 and TGF- β 2, has been shown to be inhibited by antibodies to the receptor. In the case of TGF- β 1, binding is inhibited by mannose-6-phosphate itself. See P.A. Dennis and D.B. Rifkin, Proc. Natl. Acad. Sci. USA, 88, 580-584 (1991), M.N. Lioubin, H. Marquardt, R. Roth, K.S. Kovacina and A.F. Purchio, Journal of Cellular
- 15 Biochemistry 45, 112-121 (1991) and K. Miyazano *et al.*, Annals of the New York Academy of Sciences 593, 51-58 (1990). It has not been clear whether it is desirable to prevent the generation *in vivo* of the mature active forms of TGFs or whether mannose-6-phosphate receptor binding is the only means of activating the mature protein. It has been suggested in the literature that TGF- β 1 becomes activated under various
- 20 pH conditions: see "The Transforming Growth Factor β s" in "Peptide Growth Factors and Their Receptors 1" (eds. M.B. Sporn and A.B. Roberts), Springer Verlag 1990, pages 419-472, at page 432, and references cited therein. See also K. Miyazano *et al.*, *supra*, at page 55, who mention activation by enzymes such as plasmin, cathepsin D and a glycosidase. These authors also suggest that high concentrations of sialic acid or
- 25 mannose-6-phosphate activate the latent form.

Summary of the Invention

- As recited in the parent application, it has now been found that mannose-6-phosphate (M-6-P) is useful in promoting (accelerating) wound healing, while mitigating or preventing formation of scar tissue. The term "mannose" refers herein
- 30 exclusively to the natural D-isomer. Also, mannose-1-phosphate is useful in promoting wound healing, although it does not necessarily have any anti-scarring effect. The mannose

phosphate (a term used herein collectively to refer to the 6- and 1-phosphates) can be used as such, as a pharmaceutically acceptable salt, e.g. a monosodium or disodium salt, or in any bioprecursor or "pro-drug" form effective to release the mannose phosphate into the wound area.


- 5 The present invention relates to particular formulations useful for this purpose, notably a cream, ointment or gel (which includes a vehicle or carrier), a sterile solution (which includes a physiologically acceptable diluent) and eyedrops.

Brief description of the drawings

- 10 The Figure is a graph of counts of radiolabelled hydroxyproline, a measure of collagen synthesis and deposition against time after the wounding, for wounds in rats treated with mannose-6- or 1-phosphate, glucose and a control.

Description of the preferred embodiments

The mannose-6-phosphate used in this invention is of formula (1) wherein one of R^1 and R^2 is hydrogen and the other is phosphoryl, $PO(OH)_2$.



- 20 It can be administered in the form of the free phosphoric acid or a pharmaceutically acceptable mono- or di- salt thereof, for example a sodium, calcium, magnesium or barium salt. It can also be in the form of a bioprecursor, i.e. a compound which is converted *in situ* (after application to the body) to the mannose phosphate. This could be achieved, for example, by linking a sugar alcohol group of the mannose phosphate to an appropriate acid to form an ester, in which this ester linkage is more readily hydrolysable than the phosphate linkage of mannose phosphate. Other forms of compound which will release mannose phosphate under hydrolytic, enzymatic or other conditions prevailing in the appropriate location in the body of the fibrotic condition to be treated, especially in wounds in the skin,
- 25 will be evident to chemists and are encompassed in the definition of the mannose phosphate for the purposes of this invention.

In wound healing it is contemplated that it will be desirable to apply the mannose phosphate to the wound rapidly, i.e. as soon as possible after the incision, injury, etc., normally within 48 hours, preferably within 24 hours and most preferably within 12 hours. It is believed desirable to maintain a fairly constant concentration of the mannose phosphate in the wound area for several days, e.g. up to 3 or 4 days, after wounding. A sustained release formulation of the mannose phosphate is therefore preferable. Very slow release formulations of the mannose phosphate are likely to be largely inappropriate, although formulations which allow a quick release of the threshold concentrations and thereafter slow release might be appropriate in some circumstances. In any case, slow release is likely to be useful in treating other fibrotic disorders.

General purpose formulations of the mannose phosphate in this invention include creams, ointments and gels which can be formulated in any conventional way with aqueous or oleaginous vehicles or carriers, which may also include antiseptics and other agents conventional in wound treatment; sterile injectable solutions which can be formulated with any appropriate conventional diluent, especially physiological saline; and sterile syringeable solutions of the mannose phosphate and hyaluronic acid or other polymeric fluid carrier or diluent.

Although the invention is primarily of interest in relation to skin wounds, whether arising through surgery or otherwise, including severe abrasions lacerations and burns, it is also applicable to fibrotic skin disorders, e.g. photo-damage (which is believed to up-regulate certain effectors of an increase in fibrous tissue) and irritancy and to the other disorders hereinbefore mentioned in connection with PCT Application Publication WO 91/04748 (La Jolla), the disclosure of which in relation thereto is herein incorporated by reference. Incidentally, Claim 1 of the La Jolla application calls for contacting the tissue in which extracellular matrix has accumulated with an agent which suppresses the extracellular matrix producing activity of TGF- β . The mannose phosphate used in the present invention appears not to fall within this definition.

A particularly important aspect of the invention lies in the treatment of fibrotic disorders of the eye, especially those leading to glaucoma or epi-retinal membrane formation where a tear in the eye tissue leads to fibrosis with contraction and wrinkling of

the retina. The invention includes sterile eyedrop solutions of the mannose phosphate, preferably the 6-phosphate, or salt or bioprecursor thereof.

The healing of ligaments is also improved by the mannose phosphate, preferably the 6-phosphate or salt or bioprecursor thereof.

5 The mode of application of the mannose phosphate will normally be topical, e.g. to a wound (inside and/or around it), but in appropriate cases subcutaneous or intradermal injection or implantation may be required in order better to reach the affected tissue. In extreme cases intramuscular or intravenous injection may be advisable. Preliminary data suggest that low or moderate concentrations of mannose-6-phosphate are required in order
10 to accelerate and reduce scarring in wound healing. Preferably the mannose phosphate is applied in 10-60 mM concentration to the affected area at least twice per day for at least the first three days of treatment.

The following Examples illustrate the invention. The phosphates referred to herein were in the form of their monosodium salts except glycerol-3-phosphate in Example 6 which
15 was as the disodium salt.

EXAMPLE 1

Four incisional wounds 1 cm long were made in the flanks of adult Sprague Dawley rats. Each wound extended to the depth of the underlying panniculus carnosus. In each animal one wound was left untreated as a control. The other three wounds were treated by
20 subcutaneous and intradermal injection of the surrounding skin with mannose-6-phosphate in sterile physiological saline, glucose-6-phosphate and mannose-1-phosphate respectively. Each wound was treated three times, on days 0, 1 and 2 after wounding. The rats were treated with six different concentrations of each reagent, namely 0.5, 1, 5, 20, 50 and 100 millimolar per animal per injection. All the rats were killed 7 days after wound
25 healing and the wounds were excised. The wound tissue was snap-frozen in liquid nitrogen, cryo-sectioned and stained with various antibodies to detect macrophages and monocytes (indicators of the inflammatory response), to laminin (an extracellular matrix molecule which stains basement membranes and highlights new blood vessel formation in the wound), to fibronectin (an early extracellular matrix molecule, giving an indication of
30 the amount of extracellular matrix molecules present and their orientation) and to collagen (the principal constituent of scar tissue).

The results showed that mannose-6-phosphate at 20 mM gave the best results accelerated healing, good orientation of collagen fibres, with restitution of the normal dermal architecture, followed closely by the same agent at 50 mM. Lower concentrations gave little effect, presumably through inadequate dosage. On the other hand, 100 mM gave
5 a poor result, worse than the control.

Mannose-1-phosphate performed better than the control. It accelerated wound healing but had no effect on scarring. The collagen fibres were badly oriented and there was no effect on monocytes and macrophages.

Glucose-6-phosphate gave slightly accelerated wound healing but not as much as
10 either mannose phosphate.

EXAMPLE 2

Mannose-6-phosphate (M-6-P), mannose-1-phosphate (M-1-P) and glucose (G) at 20 mM were injected into separate incisional wounds in rats for 3 days as described in Example 1. There was also a control non-injected wound. Glucose was used for
15 comparison, representing a non-phosphorylated sugar. Wounds were harvested at 3 days and at 1, 2, 3, 4, 6 and 10 weeks. The results confirmed that M-6-P and M-1-P accelerated wound healing, as shown by earlier deposition of collagen within wounds. Moreover, the M-6-P-treated wounds had slightly increased monocyte and macrophage numbers (averaging 249 monocytes and macrophages/1 week old wound compared to 201 in control
20 wounds). The wounds of the M-6-P-treated animals examined after 4, 6 and 10 weeks showed improved organisation and orientation of the collagen fibres in the dermis than those of the M-1-P- and G-treated wounds. The G-treated wounds were retarded in healing compared with controls and showed slightly increased scarring compared with controls.

EXAMPLE 3

25 Wounds were injected with 20 mM M-6-P, M-1-P and G for 3 days as described previously. A control, non-injected, wound was also used. Rats were labelled with ^3H -hydroxyproline (1 μCi /3.74 g) intraperitoneally, each at 24, 16 and 8 hours before wound harvest. Wounds were harvested under microscope with 1 mm surrounding tissue at 3 days, 1, 2, 3, 4, 6 and 10 weeks. Control (normal skin) samples were also taken.
30 Samples were then weighed.

The Figure is a plot of the specific activity of the labelled hydroxyproline in decays/minute/microgram of hydroxyproline for the excised wounds, against the time of wound harvest. Since the label was available for incorporation no longer than 24 hours before killing, the specific activity of the hydroxyproline reflects the net rate of synthesis and deposition of collagen during this 24 hour period. 3 days after wounding, the rates for the wounds and the control were the same. The rate of new collagen deposition in the control wound (filled square) increased rapidly to a maximum around the fourteenth day and remained elevated until the sixth week, before returning to the level of the normal skin control (greek phi symbol) by week ten. Both M-6-P (+) and M-1-P (larger, shaded squares) increased collagen deposition in the healing wound for 28 days post-wounding, before reducing to control wound levels. By contrast, addition of glucose (*) slightly reduced the amount of collagen deposited for the first 2 weeks after wounding, before slightly increasing collagen between 3 and 4 weeks.

EXAMPLE 4

To determine whether phosphorylation was necessary, mannose (unphosphorylated) and glyceraldehyde-3-phosphate (G-3-P) were used in healing studies. Wounds were injected with 20 mM mannose and 20 mM G-3-P for 3 days, as described previously, and harvested after 7 and 14 days. Both these molecules gave similar results to glucose, i.e. delayed the wound healing response, suggesting that phosphorylation of mannose is required for accelerated healing, and gave no anti-scarring activity.

EXAMPLE 5

This Example shows the effects of increasing the frequency of application to the wound.

Experimental rats were wounded as described earlier and the wounds treated with nothing (control), 20 mM mannose-6-phosphate (M-6-P) 20 mM mannose-1-phosphate (M-1-P) or 20 mM mannose. However, instead of being given a single injection on days 0, 1 and 2, wounds were injected every 8 hours on days 0, 1 and 2. Wounds were harvested after 7 and 14 days and processed for histology and immunocytochemistry.

As previously, mannose-6-phosphate (M-6-P) accelerated wound healing as assayed by earlier collagen deposition within the wound (as did M-1-P) and also markedly reduced scarring. The organisation of the collagen within the wound was greatly improved and the

anti-scarring effect of M-6-P was better than in the wounds treated by a single injection on days 0, 1 and 2. These data suggest that more frequent application of mannose-6-phosphate on the first 3 days following wounding gives an improved anti-scarring effect. No other treatment gave any anti-scarring effect.

5

EXAMPLE 6

This Example compares the effects of other phosphorylated sugars. This experiment was similar in design to all previous. Wounds were either unmanipulated (control) or treated by injection with 20 mM glycerol-3-phosphate, 20 mM galactose-6-phosphate, 20 mM mannose-6-phosphate or 20 mM galactose. The wounds
10 were harvested on days 7 and 14 and 6 and 8 weeks after wounding. Two groups of animals were studied, those which were injected every 8 hours on days 0, 1 and 2 after wounding and those injected once on days 0, 1 and 2 post wounding. All histological sections were analysed by connective tissue staining and immunocytochemistry as previously described.

15 The results confirmed that application of 20 millimolar M-6-P at 8 hourly intervals on days 0, 1 and 2 after wounding, gave the best results. Wound healing was accelerated by early deposition of collagen within the wound and the treatment had marked anti-scarring activity. The wounds showed a more normal organisation of collagen fibrils within the dermis.

20 Galactose, galactose-6-phosphate and glycerol-3-phosphate showed no effect, wounds being similar, or if anything, slightly worse, than the control in terms of speed of healing and final scarring result.

CLAIMS

1. A cream, ointment or gel for topical application comprising mannose-6-
or 1-phosphate or a pharmaceutically acceptable salt or bioprecursor thereof and a
pharmaceutically acceptable vehicle or carrier.
- 5 2. A sterile solution suitable for injection or syringe application comprising
mannose-6- or 1-phosphate or a pharmaceutically acceptable salt or bioprecursor thereof
and a physiologically acceptable diluent or carrier.
3. A sterile solution suitable for use as eyedrops comprising mannose-6-
or 1-phosphate or a pharmaceutically acceptable salt or bioprecursor thereof and a
10 physiologically acceptable diluent.



Application No: GB 9607420.8
Claims searched: 1-3

Examiner: John Jenkins
Date of search: 1 July 1996

Patents Act 1977
Search Report under Section 17

Databases searched:

UK Patent Office collections, including GB, EP, WO & US patent specifications, in:

UK CI (Ed.O): A5B(BFE,BHA,BKE,BLB,BLD,BLF)

Int CI (Ed.6): A61K 9/06,9/08

Other: ONLINE: WPI, DIALINDEX(MEDICINE), CAS-ONLINE

Documents considered to be relevant:

Category	Identity of document and relevant passage	Relevant to claims
X	GB 1311956 (MERCK) See Example 15	2 & 3
A	WO 91/09604 A1 (PERSTORP) See claim 11, page 2 lines 21-24 and page 8 last line	
X	WO 90/01938 A1 (AUSTRALIAN NATIONAL UNIVERSITY) See Examples 3 & 4	2 & 3
X	Chemical Abstracts 119:15132 & JP 050058868 A2 (KAO CORPORATION)	1

10

X	Document indicating lack of novelty or inventive step	A	Document indicating technological background and/or state of the art.
Y	Document indicating lack of inventive step if combined with one or more other documents of same category.	P	Document published on or after the declared priority date but before the filing date of this invention.
&	Member of the same patent family	E	Patent document published on or after, but with priority date earlier than, the filing date of this application.